Award-winning freelance medical writer with 15+ years of experience. I craft meaningful content for hospitals, researchers and health care brands. Got a project? Email me at hello@banajobe.com.
Speed Rare Disease and Specialty Drugs to Market With AI
Despite high awareness of AI and ML tools, some biopharma leaders may overlook opportunities to use automation as they take their programs to market. Inside this report, we’ll explore those potentially untapped areas as we unpack IPM.ai's latest survey results in the context of what’s next in a new era of AI-supported launch planning.
How Pharma Is Increasing Patient Support With Self-Service Options
As more consumers embrace self-service as part of everyday life, it makes sense that patients would want that same experience from a hub program. How do your patient access and support services plan to evolve?
AI, ML, and a New Epoch for Clinical Trials
Biopharma organizations are exploring artificial intelligence across multiple use cases: patient identification, data analysis, regulatory submissions, and beyond. Along the way, they’re seeing both short- and long-term success; some changes are fast, and others are slow.
Webinar: Overcoming the Chasm Between Payer Policy and Real-Life Practice
Pharma companies traditionally rely on payer coverage data, including formularies and restrictions, to understand the contours of their market access barriers. While these inputs are certainly valuable, they can create an incomplete picture. That’s why manufacturers are increasingly relying on real-world data (RWD) to uncover the blind spots in their market access analysis.
Health equity amid a decentralized care landscape: How pharmacists can adapt and prepare
As healthcare in the US continues to decentralize, pharmacists can prepare for delivering more equitable care to patients in their community.
Balancing the promises and realities of precision medicine
Precision medicine has been given ambitious descriptors: a miracle, a marvel, even a panacea. Consumers are plugging into the hype, with a recent survey commissioned by Wolters Kluwer finding that 68% of Americans believe their own DNA could help guide their providers’ prescription decisions. But at the other end of those hopeful expectations are the sobering realities of genomic innovations that haven’t yet found sweeping success.
Genetic code or ZIP code? Equitable pharmacogenetics accounts for both
Precision medicine is poised to impact consumers’ medications. What should pharmacists and clinicians understand about the impact of both genetics and social determinants before giving a prescription?
What the FDA’s guidance on diversity means for rare disease sponsors
For rare disease trials, which are already challenging to enroll, the new guidance introduces nuances that speak to broader recruitment trends in orphan drugs. Here's what sponsors should know when approaching "rarified" rare disease protocols.
Vaccine Trend Report: The Latest Challenges & Opportunities
The awareness, investments, and enthusiasm surrounding vaccine research is at an all-time high. At the same time, challenges in pushing vaccine trials forward remain, and many barriers are more palpable now than ever before.
Maintain an agile copay program in a changing policy environment
How biopharma companies can preempt threats to copay assistance with a more comprehensive approach to patient support.
How to Develop an Inclusive Patient-Centric Hub for Your Product’s Launch
BioPharma companies utilizing patient support hubs that offer wrap-around care have seen dramatic increases in access, affordability and adherence. What used to involve simple patient assistance and therapy access has evolved into dynamic systems that track, anticipate and offer resources to patients.
Reducing health disparities through community health center partnerships
Health systems have an opportunity to partner with community health centers to reduce medical mistrust among historically marginalized groups, impacting health outcomes and equity.
Developing clinical empathy to improve health equity
To improve health equity, clinicians need to develop, showcase, and implement clinical empathy in their care delivery to help rebuild decades of medical mistrust among marginalized groups.
A Guide to Overcoming HIPAA’s Tensions Between Access & Security
With protected health information (PHI) dispersed across wearables, apps, portals, and other places, more companies than ever have access to sensitive data, and that access comes with serious responsibilities. But businesses need to use data, so this creates a tension – a push and pull between access and security. As organizations attempt to make data less vulnerable, they may also make it less usable. And what good is that?
The State of DEI in Clinical Trials
While the clinical research industry has taken steps toward more diversity, equity, and inclusion (DEI) within research and development, the gains should be taken in the context of the systemic barriers that remain. Despite stakeholders becoming more intentional and determined about trial diversity and FDA guidance to make trials more representative, there is more to be done to put R&D to work for everyone.